KR20220151393A - Health functional tea composition for stress relief containing ginseng - Google Patents
Health functional tea composition for stress relief containing ginseng Download PDFInfo
- Publication number
- KR20220151393A KR20220151393A KR1020210058584A KR20210058584A KR20220151393A KR 20220151393 A KR20220151393 A KR 20220151393A KR 1020210058584 A KR1020210058584 A KR 1020210058584A KR 20210058584 A KR20210058584 A KR 20210058584A KR 20220151393 A KR20220151393 A KR 20220151393A
- Authority
- KR
- South Korea
- Prior art keywords
- comparative example
- tea composition
- composition
- stress
- health functional
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 55
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 15
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 15
- 230000036541 health Effects 0.000 title claims abstract description 14
- 235000020542 functional tea Nutrition 0.000 title claims description 8
- 241000208340 Araliaceae Species 0.000 title description 13
- 240000004670 Glycyrrhiza echinata Species 0.000 claims abstract description 16
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims abstract description 16
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 16
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims abstract description 16
- 229940010454 licorice Drugs 0.000 claims abstract description 16
- 244000269722 Thea sinensis Species 0.000 claims abstract 5
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract 2
- 239000002994 raw material Substances 0.000 claims description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 244000025221 Humulus lupulus Species 0.000 claims description 6
- 235000008694 Humulus lupulus Nutrition 0.000 claims description 6
- 244000178870 Lavandula angustifolia Species 0.000 claims description 6
- 241000219925 Oenothera Species 0.000 claims description 6
- 235000004496 Oenothera biennis Nutrition 0.000 claims description 6
- 239000001102 lavandula vera Substances 0.000 claims description 6
- 244000062730 Melissa officinalis Species 0.000 claims description 5
- 235000010654 Melissa officinalis Nutrition 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 4
- 235000001835 Madeira lavender Nutrition 0.000 claims description 3
- 235000001793 lemon lavender Nutrition 0.000 claims description 3
- 238000005520 cutting process Methods 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 238000002791 soaking Methods 0.000 claims description 2
- 241000411851 herbal medicine Species 0.000 abstract description 7
- 235000013376 functional food Nutrition 0.000 abstract description 4
- 208000004232 Enteritis Diseases 0.000 abstract description 2
- 206010043269 Tension headache Diseases 0.000 abstract description 2
- 208000008548 Tension-Type Headache Diseases 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 49
- 241001122767 Theaceae Species 0.000 description 27
- 206010016256 fatigue Diseases 0.000 description 25
- 230000000694 effects Effects 0.000 description 16
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 14
- 239000000284 extract Substances 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 10
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 9
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 8
- 229960000890 hydrocortisone Drugs 0.000 description 7
- 230000006872 improvement Effects 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 235000014655 lactic acid Nutrition 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 206010019233 Headaches Diseases 0.000 description 5
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 231100000869 headache Toxicity 0.000 description 5
- 230000003340 mental effect Effects 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 4
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 4
- 206010024264 Lethargy Diseases 0.000 description 4
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
- 235000007516 Chrysanthemum Nutrition 0.000 description 3
- 235000010663 Lavandula angustifolia Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000002929 anti-fatigue Effects 0.000 description 3
- 230000002180 anti-stress Effects 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000517 effect on sleep Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000018219 lavender Nutrition 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 240000005250 Chrysanthemum indicum Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 2
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 2
- 208000019914 Mental Fatigue Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 244000126014 Valeriana officinalis Species 0.000 description 2
- 235000013832 Valeriana officinalis Nutrition 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000037081 physical activity Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 235000016788 valerian Nutrition 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000000759 Lepidium meyenii Species 0.000 description 1
- 235000000421 Lepidium meyenii Nutrition 0.000 description 1
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000020510 functional beverage Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 235000012902 lepidium meyenii Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 208000030208 low-grade fever Diseases 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 208000022925 sleep disturbance Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000003817 vacuum liquid chromatography Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/34—Tea substitutes, e.g. matè; Extracts or infusions thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/06—Treating tea before extraction; Preparations produced thereby
- A23F3/14—Tea preparations, e.g. using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/163—Liquid or semi-liquid tea extract preparations, e.g. gels, liquid extracts in solid capsules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/18—Extraction of water soluble tea constituents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/40—Tea flavour; Tea oil; Flavouring of tea or tea extract
- A23F3/405—Flavouring with flavours other than natural tea flavour or tea oil
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2124—Ginseng
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/14—Extraction
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 인삼을 함유하는 스트레스 개선용 건강기능성 차 조성물에 관한 것이다. 보다 자세하게는 본 발명은 인삼, 감초, 백출, 복령 및 각종 생약을 함유하여 스트레스 완화 기능이 있는 침출차 조성물에 관한 것이다. The present invention relates to a health functional tea composition for stress relief containing ginseng. More specifically, the present invention relates to a leachate composition having a stress relieving function by containing ginseng, licorice, baekchul, bokryeong and various herbal medicines.
피로는 때때로 "활동을 수행하기 위해 필요한 자원들의 가용, 활용 및 회복에서의 불균형으로 인한 신체적 및 정신적 활성에 대한 감소된 능력의 지각"으로 정의 될 수 있으며, 구체적으로는 fatigue는 주로 육체적 피로로 작업능력이 저하되는 상태, 그리고 stress는 정신적 피로로 항산성의 혼란이 일어나는 상태를 말한다(식약청 건강기능식품의 피로회복 관련 기능성 평가체계 구축, 연구보고서). 피로는 중추신경계 피로, 신경-근육의 접합부의 피로와 지체의 말초 피로로 분류된다. 피로는 다양한 생리학적 및 생화학적 인자를 비롯한 포괄적인 생리학인 과정이며, 신체의 정신 활동이나 신체활동이 일정한 단계에 도달할 때 필연적으로 나타나는 정신적인 생리현상이다. 이는 인체 본래의 작업 능력이 일시적으로 저하되는 것을 의미하고, 신체가 손상 상태로 발전하는 것을 나타내는 증상일 수 있다. Fatigue can sometimes be defined as "a perception of reduced capacity for physical and mental activity due to an imbalance in the availability, utilization and recovery of resources necessary to perform an activity", specifically fatigue is primarily physical exhaustion at work. A state in which ability is reduced, and stress refers to a state in which acid resistance is disrupted due to mental fatigue (KFDA Health Functional Food Fatigue Recovery Related Functional Evaluation System Establishment, Research Report). Fatigue is classified into central nervous system fatigue, nerve-muscular junction fatigue, and peripheral fatigue of the limbs. Fatigue is a comprehensive physiological process including various physiological and biochemical factors, and is a mental physiological phenomenon that inevitably appears when the body's mental activity or physical activity reaches a certain level. This means that the original working capacity of the human body is temporarily lowered, and may be a symptom indicating that the body is developing into a damaged state.
피로가 지속적으로 발생하면 만성적인 상태가 되면 만성피로 증후군이라는 질병으로 발전되기도 한다. 현재 만성 피로 증후군(Chronic Fatigue Syndrome, CFS)의 주요 증상으로 장기간 지속되는 피로감은 미열, 두통, 인후통, 근육 관절통, 주의력 집중 장애, 기억력 저하, 수면 장애 및 우울증 등의 비특이적인 증상과 함께 갖는 일군의 증후군이고, 신체검사와 상규검사의 경우 일반적으로 뚜렷한 이상이 없다(Holmes GO, er al, Amm. Intern Med, 1988, 108 (3)). 피로를 일으키는 원인으로는 수면부족, 운동부족, 불균형 식이, 알코올 중독과 같은 나쁜 습관, 정신적 압박, 나쁜 작업 환경, 직장 환경 등 다양하다.If fatigue continues to occur, it may develop into a disease called chronic fatigue syndrome when it becomes a chronic condition. Currently, the main symptom of Chronic Fatigue Syndrome (CFS) is long-lasting fatigue, which is a group of non-specific symptoms such as low-grade fever, headache, sore throat, muscle and joint pain, difficulty concentrating attention, memory loss, sleep disturbance, and depression. It is a syndrome, and there is usually no obvious abnormality in physical examination and routine examination (Holmes GO, er al, Amm. Intern Med, 1988, 108 (3)). There are many causes of fatigue, such as lack of sleep, lack of exercise, unbalanced diet, bad habits such as alcoholism, mental pressure, bad work environment, and work environment.
피로 완화방법으로는 휴식을 취하는 방법, 만족스러운 일을 찾는 것, 규칙적인 운동, 더 나은 식이로의 변화 및 충분한 잠을 포함하는 여러 가지 접근 방법들이 존재한다. 하지만, 특정한 피로 해소 방법 수행으로 육체적 및 생리적인 피로감을 단기에 해소하기는 어려움이 있다. 따라서 육체적 및 정신적인 피로감 해소, 특히 면역력 저하, 신경계 및 내분비계의 장애, 비정상적인 혈관계 및 소화 장애 등의 극복에 도움을 주는 제품개발이 요구되나 이에 관련된 효과를 갖는 제품 개발은 아직 없는 상황이며, 카페인 같은 각성효과를 가지는 약물이 피로개선을 위한 약물로 사용되고 있으나 실제 혈중 피로물질을 감소시키는 효과는 없다.There are several approaches to alleviating fatigue, including taking breaks, finding satisfying work, regular exercise, changing to a better diet and getting enough sleep. However, it is difficult to relieve physical and physiological fatigue in a short period of time by performing a specific fatigue relieving method. Therefore, it is required to develop products that help overcome physical and mental fatigue, especially reduced immunity, disorders of the nervous and endocrine systems, abnormal vascular system and digestive disorders, but there is no development of products with related effects yet. Caffeine A drug having the same awakening effect is used as a drug for improving fatigue, but there is no effect of reducing fatigue substances in the blood.
이에 본 발명자들은 인삼을 주원료로 하는 생약재 혼합 조성물을 침출차 형태로 제조하여 이를 수시로 음용할 수 있는 피로회복제 음료 제형 형태로 제공함으로써 본 발명을 완성하게 되었다. Accordingly, the inventors of the present invention completed the present invention by preparing a mixed herbal medicine composition using ginseng as a main ingredient in the form of leach tea and providing it in the form of a drink formulation for fatigue recovery that can be consumed at any time.
본 발명의 목적은 인삼을 함유하는 스트레스 개선용 건강기능성 차 조성물을 제공하는 데에 있다. 보다 자세하게는 본 발명의 목적은 인삼, 감초, 백출, 복령 및 각종 생약을 함유하여 스트레스 완화 기능이 있는 차 조성물을 제공하는 데에 있다. An object of the present invention is to provide a health functional tea composition for stress relief containing ginseng. More specifically, an object of the present invention is to provide a tea composition having a stress relieving function by containing ginseng, licorice, baekchul, bokryeong and various herbal medicines.
본 발명은 인삼, 감초, 백출, 복령을 함유하는 스트레스 개선용 건강기능성 차 조성물에 관한 것이다. The present invention relates to a health functional tea composition for stress relief containing ginseng, licorice, baekchul, and bokryeong.
상기 차 조성물에는 길초근, 달맞이꽃 종자, 감국, 감초, 홉, 레몬밤 및 라벤더가 첨가될 수 있다. Valerian root, evening primrose seed, gamguk, licorice, hops, lemon balm and lavender may be added to the tea composition.
상기 차 조성물에는 인삼 100 중량부 기준으로, 감초 80~200 중량부, 백출 100~170 중량부, 복령 100~150 중량부가 함유될 수 있다. 또한 인삼 100 중량부 기준으로, 길초근 5~10 중량부, 달맞이꽃 종자 10~20 중량부, 감국 5~10 중량부, 감초 5~10 중량부, 홉 5~10 중량부, 레몬밤 5~10 중량부 및 라벤더 5~10 중량부가 더 포함될 수 있다. The tea composition may contain 80 to 200 parts by weight of licorice, 100 to 170 parts by weight of Baekchul, and 100 to 150 parts by weight of Bokryeong, based on 100 parts by weight of ginseng. In addition, based on 100 parts by weight of ginseng, 5-10 parts by weight of valerian roots, 10-20 parts by weight of evening primrose seeds, 5-10 parts by weight of chrysanthemum, 5-10 parts by weight of licorice, 5-10 parts by weight of hops, 5-10 parts by weight of lemon balm 5 to 10 parts by weight and lavender may be further included.
상기 차 조성물은 건조된 각 원료 시료를 1~2cm 길이로 세절하여 준비한 후, 세절된 각 원료 시료를 물에 불린 후 160~170℃에서 8~12분 동안 가열하여 덖음하고, 30℃ 이하로 식히는 과정을 3~4회 반복하되, 반복할 때마다 덖음 온도를 8~10℃씩 낮추어 덖음하여 제조할 수 있다. The tea composition is prepared by cutting each dried raw material sample into 1-2 cm lengths, soaking each raw material sample in water, heating it at 160-170 ° C. for 8-12 minutes, and cooling it below 30 ° C. The process is repeated 3 to 4 times, but each time it is repeated, it can be prepared by lowering the roasting temperature by 8 to 10 ° C.
상기 차 조성물은 침출차로 제공되기 위해, 덖음한 원료 상태로 그대로 제공되거나 티백에 소분하여 제공되는 것이 바람직하나, 필요에 따라 추출물 형태로도 제공될 수 있다. 추출물 제조시, 용매로서 물, C1~C4 알코올 또는 이들의 혼합용액을 사용하여 추출할 수 있으며, 상기 C1~C4 알코올은 메탄올, 에탄올, 프로판올, 이소프로판올, 부탄올 및 이소부탄올로 이루어진 군에서 선택될 수 있다. 이 때 용매로서 바람직하게는 물을 사용하는 것이 더 좋다. 상기 용매는 원료 시료들의 총 중량의 1~40배 중량 또는 부피를 사용할 수 있으며, 추출조건은 20~100℃에서 1분~48시간일 수 있다. 상기 과정은 1~4번까지 반복할 수 있다. 상기 추출물의 제조시, 추출용 기기로는 통상의 추출기기, 초음파분쇄추출기 또는 분획기를 이용할 수 있다. 이렇게 제조된 추출물 또는 분획물은 열풍건조, 감압건조 또는 동결건조하여 용매를 제거할 수 있다. 또한, 상기 추출물은 칼럼크로마토그래피를 이용하여 정제하여 사용할 수 있다. In order to provide the tea composition as leached tea, it is preferable to provide the raw material as it is or to be provided in small portions in tea bags, but may also be provided in the form of an extract if necessary. When preparing the extract, it may be extracted using water, C1-C4 alcohol or a mixture thereof as a solvent, and the C1-C4 alcohol may be selected from the group consisting of methanol, ethanol, propanol, isopropanol, butanol and isobutanol have. At this time, it is better to use preferably water as a solvent. The solvent may be used in a weight or volume 1 to 40 times the total weight of raw samples, and the extraction condition may be 1 minute to 48 hours at 20 to 100 ° C. The above process may be repeated from 1 to 4 times. When preparing the extract, a conventional extraction device, an ultrasonic crushing extractor, or a fractionator may be used as an extraction device. The solvent may be removed from the extract or fraction thus prepared by hot air drying, vacuum drying or lyophilization. In addition, the extract can be used after being purified using column chromatography.
상기 추출물 또는 분획물은 상법에 따라, 유기용매(알코올, 에테르, 아세톤 등)에 의한 추출, 헥산과 물의 분배, 칼럼크로마토그래피에 의한 방법 등, 식물체 성분의 분리 추출에 이용되는 공지의 방법을 단독 또는 적합하게 조합한 방법을 이용하여 분획 또는 정제하여 사용할 수 있다. The extracts or fractions are obtained by a known method used for separation and extraction of plant components, such as extraction with an organic solvent (alcohol, ether, acetone, etc.), partitioning of hexane and water, and column chromatography according to a conventional method, alone or It may be used after fractionation or purification using a suitably combined method.
상기 크로마토그래피는 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 엘에이취-20 컬럼 크로마토그래피(LH-20 column chromatography), 이온교환수지 크로마토그래피(ion exchange resin chromatography), 중압 액체 크로마토그래피(medium pressure liquid chromatography), 박층 크로마토그래피(TLC; thin layer chromatography), 실리카겔 진공 액체 크로마토그래피(silica gel vacuum liquid chromatography) 및 고성능 액체 크로마토그래피(high performance liquid chromatography) 중에서 선택될 수 있다. The chromatography is silica gel column chromatography, LH-20 column chromatography, ion exchange resin chromatography, medium pressure liquid chromatography chromatography), thin layer chromatography (TLC), silica gel vacuum liquid chromatography, and high performance liquid chromatography.
본 발명에서 상기 추출물이 제공될 경우, 이를 함유하는 스트레스 완화용 건강기능식품의 제공이 가능한데, 상기 추출물은 그대로 식품으로도 이용가능하나 정제, 캡슐제, 환제 또는 액제 등의 형태로도 제공될 수 있다. 본 발명의 추출물을 첨가할 수 있는 식품으로는, 예를 들어, 각종 드링크제, 육류, 소세지, 빵, 캔디류, 스넥류, 면류, 아이스크림, 유제품, 스프, 이온음료, 음료수, 알코올 음료, 껌, 차 및 비타민 복합제 등이 있다. When the extract is provided in the present invention, it is possible to provide a health functional food for relieving stress containing it, and the extract can be used as food as it is, but it can also be provided in the form of tablets, capsules, pills or liquids. have. Foods to which the extract of the present invention can be added include, for example, various drinks, meat, sausages, bread, candies, snacks, noodles, ice cream, dairy products, soups, ionic beverages, beverages, alcoholic beverages, gum, tea and Vitamin complexes, etc.
본 발명은 인삼, 감초, 백출, 복령 및 각종 생약을 함유하여 스트레스 완화 기능이 있는 차 조성물에 관한 것으로서, 상기 긴장성 두통이나 스트레스가 원인이 되는 과민성 장염 등을 개선하는 효과가 우수하고 차 형태로 제조되어 직장인이나 수험생 등이 쉽게 접할 수 있는 건강기능식품으로서 용이하게 이용될 수 있다.The present invention relates to a tea composition having a stress relieving function containing ginseng, licorice, baekchul, bokryeong, and various herbal medicines, and is excellent in improving the tension headache or stress-induced irritable enteritis, etc. It can be easily used as a health functional food that office workers or students can easily access.
이하 본 발명의 바람직한 실시예를 상세히 설명하기로 한다. 그러나, 본 발명은 여기서 설명되는 실시예에 한정되지 않고 다른 형태로 구체화될 수도 있다. 오히려, 여기서 소개되는 내용이 철저하고 완전해지도록, 당업자에게 본 발명의 사상을 충분히 전달하기 위해 제공하는 것이다. Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms. Rather, it is provided to sufficiently convey the spirit of the invention to those skilled in the art, so that the disclosure herein will be thorough and complete.
<실시예 1 및 2. 차 조성물의 제조><Examples 1 and 2. Preparation of tea composition>
건조 상태의 인삼, 감초, 백출, 복령, 길초근, 달맞이꽃 종자, 감국, 감초, 홉, 레몬밤 및 라벤더를 차 원료로 구입한 후 1~2cm 길이로 세절하였다. 각 원료 시료에 물을 일정량씩 부어 원료 시료에 수분이 충분히 머금게 하였다. 이 때 물을 별도로 버리지 않고 원료만 불려져서 바로 덖음하기 좋은 상태가 되도록 물을 조금씩 부어주었다. After purchasing dried ginseng, licorice, baekchul, bokryeong, gilchogeun, evening primrose seeds, gamguk, licorice, hops, lemon balm and lavender as tea raw materials, they were cut into 1-2cm lengths. A certain amount of water was poured into each raw material sample to ensure that the raw material sample was sufficiently hydrated. At this time, water was poured little by little so that only the raw materials were soaked without discarding the water, so that it was in a good state to cook immediately.
다음으로 각 원료 시료를 160~170℃에서 8~12분 동안 가열하여 덖음하고, 30℃ 이하로 식히는 과정을 4회씩 반복하였으며, 반복할 때마다 덖음 온도를 8~10℃씩 낮추어 덖음하였다. 또한 덖음후 식히는 과정에서 원료 시료를 지속적으로 치대어 유념하였다. Next, each raw material sample was heated at 160 ~ 170 ℃ for 8 ~ 12 minutes, and the process of cooling to 30 ℃ or less was repeated four times, and each time it was repeated, the roasting temperature was lowered by 8 ~ 10 ℃. In addition, in the process of cooling after roasting, raw material samples were continuously kneaded and kept in mind.
덖음과정을 모두 마친 각 원료는 수분함량 15 중량% 이하로 건조하여 하기 표 1의 조건으로 혼합하였다. Each raw material after the roasting process was dried to a moisture content of 15% by weight or less and mixed under the conditions shown in Table 1 below.
<비교예 1 및 2. 비교조건 차 조성물의 제조 a> <Comparative Examples 1 and 2. Preparation of comparative condition tea composition a>
실시예 1에서와 같이 차 원료를 제조한 후 하기 표 2의 조건으로 혼합하여 차 조성물을 제조하였다. After preparing tea raw materials as in Example 1, a tea composition was prepared by mixing them under the conditions shown in Table 2 below.
<비교예 3. 비교조건 차 조성물의 제조 b><Comparative Example 3. Preparation of comparative condition car composition b>
비교예 3-1Comparative Example 3-1
실시예 1-1과 같은 함량으로 차 원료를 준비하되 덖음 과정을 수행하지 않은 차 원료를 그대로 혼합하여 차 조성물로 준비하였다. The tea raw materials prepared in the same content as in Example 1-1, but the tea raw materials that were not roasted were mixed as they were to prepare a tea composition.
비교예 3-2Comparative Example 3-2
실시예 2-1과 같은 함량으로 차 원료를 준비하되 덖음 과정을 수행하지 않은 차 원료를 그대로 혼합하여 차 조성물로 준비하였다. The tea raw materials prepared in the same content as in Example 2-1, but the tea raw materials that were not roasted were mixed as they were to prepare a tea composition.
비교예 3-3Comparative Example 3-3
실시예 2-1과 같은 함량으로 차 원료를 준비하되 덖음 과정의 온도를 모두 160~170℃에서 수행하였다. Tea raw materials were prepared in the same content as in Example 2-1, but the temperature of the roasting process was all performed at 160 to 170 ° C.
<실험예 1. 항 스트레스 효과 확인><Experimental Example 1. Confirmation of anti-stress effect>
실험예 1-1. 구속 스트레스 유도 및 혈액채취Experimental Example 1-1. Restraint stress induction and blood collection
실험동물로 체중 170~180 g 범위의 Sprague-Dawley의 수컷 흰쥐를 (주)대한바이오링크(음성, 한국)에서 구입하였다. 사육환경은 온도 20±2℃, 습도 55±1%(RH), 명암주기 12시간 간격으로 유지하여 1주일간 순환시켰다. 사료는 실험동물용 고형사료 (PMI Nutrition International)를 매일 일정한 시간에 일정량을 주었고, 음용수로는 멸균수를 물병을 이용하여 자유롭게 섭취하도록 하였다. As experimental animals, male Sprague-Dawley rats weighing 170-180 g were purchased from Daehan Biolink Co., Ltd. (Eumseong, Korea). The breeding environment was maintained at a temperature of 20 ± 2 ° C, humidity of 55 ± 1% (RH), and a light-dark cycle at 12-hour intervals, and was cycled for one week. Feed was given a certain amount of solid feed for laboratory animals (PMI Nutrition International) at a constant time every day, and sterilized water was freely consumed using a water bottle as drinking water.
시료투여는 실시예/비교예 각 조성물을 10배 중량의 80℃ 열수에 1시간 추출한 추출물을 식혀 하루에 1㎖씩 2주간 투여하였고, 이 후 각 실험동물에 구속 스트레스를 가했다. For sample administration, the extract obtained by extracting 10 times the weight of each composition in 80° C. hot water for 1 hour was cooled and administered 1 ml per day for 2 weeks, after which restraint stress was applied to each experimental animal.
구속 스트레스를 가하는 방법은 실험동물을 투명 case(40cm×30cm×30cm)안에 넣어 매일 17:00∼18:00에 1시간씩 case를 진동기에 올려놓은 다음 진동(2km/hr)시키는 방법으로 7일간 실시하였다. 이 때 구속 스트레스를 가하는 기간에도 각 조성물을 투여하였다.The method of applying restraint stress is to put the experimental animal in a transparent case (40cm × 30cm × 30cm), place the case on a vibrator for 1 hour every day from 17:00 to 18:00, and then vibrate (2km/hr) for 7 days. conducted. At this time, each composition was administered even during the period of applying the restraint stress.
7일간의 구속 스트레스 완료 10분 후에 각 실험동물을 마취한 다음 희생하여 분석시료(혈청 혹은 혈장 등)를 채취하여, 다음의 실험에서 항 스트레스 효과를 평가하기 위한 바이오메커로서 혈액에서의 코티솔(cortisol), 젖산(lactic acid), 글루코오스(glucose), 크레아틴 포스포키나아제(creatine phosphokinase)의 양을 측정하였다. After 10 minutes of completion of the restraint stress for 7 days, each experimental animal was anesthetized, sacrificed, and analyzed samples (serum or plasma, etc.) were collected, and cortisol (cortisol in blood) as a biomechanical to evaluate the anti-stress effect in the following experiment ), lactic acid, glucose, and creatine phosphokinase were measured.
실험예 1-2. 혈액 내 코티솔(Cortisol)의 양 비교 Experimental Example 1-2. Comparison of the amount of cortisol in the blood
스트레스가 유발될 때, 인체에서는 코티솔을 분비하여 대사율을 떨어트리고, 대뇌의 식욕중추를 자극하여 허기가 지지 않아도 음식물 섭취를 하도록 작용한다(Adam TC, Epel ES. Stress, eating and the reward system. Physiology and Behavior. 2007. 91(4):449-458).When stress is induced, the human body secretes cortisol to decrease the metabolic rate and stimulates the appetite center of the brain to allow food intake even when there is no hunger (Adam TC, Epel ES. Stress, eating and the reward system. Physiology and Behavior. 2007. 91(4):449-458).
이에 구속 스트레스 유도 후 각 조성물이 투여된 동물의 혈액 내 코티솔(Cortisol)의 양을 표 3에 나타내었다. Accordingly, Table 3 shows the amount of cortisol in the blood of animals to which each composition was administered after induction of restraint stress.
혈중 코티솔 함량 (㎍/㎗)after restraint stress
Blood cortisol content (μg/dl)
표 3에서 보듯이, 혈중 코티솔이 실시예 1 및 2의 차 조성물을 투여한 군은 구속 스트레스만을 유도한 군과 비교하여 월등히 적은 것으로 확인된다. As shown in Table 3, it was confirmed that the blood cortisol of the group administered with the tea compositions of Examples 1 and 2 was significantly lower than that of the group inducing only restraint stress.
실험예 1-3. 혈액 내 젖산(lactic acid)의 양 비교Experimental Example 1-3. Comparison of the amount of lactic acid in the blood
육체적/정신적 스트레스는 근육에 젖산을 축적시켜 피로를 야기하는데, 젖산의 축적에는 피루브산으로부터 젖산의 생성을 촉매하는 근세포질의 LDH(lactate dehydrogenase)가 관여한다(Fitts et al., Am J Physiology. 1976. 23(2);430-433). Physical/mental stress causes fatigue by accumulating lactic acid in muscles, and lactate dehydrogenase (LDH), which catalyzes the production of lactic acid from pyruvic acid, is involved in the accumulation of lactic acid (Fitts et al., Am J Physiology. 1976. 23(2);430-433).
이에 구속 스트레스 유도 후 각 조성물이 투여된 동물의 혈액 내 젖산(Lactic acid)의 양을 표 4에 나타내었다.Accordingly, Table 4 shows the amount of lactic acid in the blood of animals to which each composition was administered after induction of restraint stress.
혈중 젖산 함량(㎍/㎗)after restraint stress
Blood lactate content (μg/dl)
표 4에서 보듯이, 실시예 1 및 2의 차 조성물 섭취군은 혈액 내 글루코스 양이 줄어들었고, 구속 스트레스만을 유도한 군과 비교하여 현저히 낮은 것으로 파악된다. As shown in Table 4, the amount of glucose in the blood was reduced in the group ingesting the tea composition of Examples 1 and 2, and it was found to be significantly lower than the group inducing only restraint stress.
<< 실험예Experimental example 2. 복용 테스트 - 두통, 무기력감 개선효과 확인> 2. Dosage test - Check the effect of improving headache and lethargy>
실시예 1 및 2, 비교예 1 내지 3의 각 차 조성물을 10g 티백으로 제공하여 각 7명씩 40~60대의 남녀노소에게 20일간, 매일 하루에 3번씩 식후 1시간 후에 약 70℃의 온수에 5분 이상 침출하여 음용하게 하였으며, 20일간의 복용 후 두통, 무기력감 개선 등의 정도를 하기 표 9에 5점 리커트측정법(5점 : 아주 우수, 4점 : 우수함, 3점 : 보통, 2점 : 나쁨, 1점 : 아주 나쁨)으로 각 조성물의 복용 전과 비교하여 나타내게 하였다. 이를 위해 두통 개선 효과, 무기력감 개선 효과와 이러한 증상으로 인해 유도되는 숙면 효과, 정장 효과, 전체적인 피로감 개선 효과 등을 확인하여 표 5에 나타내었다.Each of the tea compositions of Examples 1 and 2 and Comparative Examples 1 to 3 was provided in 10 g tea bags, and 7 people each in their 40s to 60s, men and women of all ages, 20 days, 3 times a day, 1 hour after eating, in hot water at about 70 ° C. It was leached for more than 20 minutes and drunk, and after 20 days of taking, the degree of improvement in headache and lethargy was measured using a 5-point Likert measurement method (5 points: very good, 4 points: excellent, 3 points: normal, 2 points: Poor, 1 point: Very bad) was compared with before taking each composition. To this end, the headache improvement effect, the lethargy improvement effect, the sleep effect induced by these symptoms, the formality effect, and the overall fatigue improvement effect were confirmed and shown in Table 5.
표 5에서 보듯이, 실시예 1 및 2의 조성물을 처리한 군에서는 비교예 1 내지 3의 차 음용군에 비해 숙면효과, 무기력감 개선효과 및 피로감 개선효과가 있었음을 알 수 있다. As shown in Table 5, it can be seen that the group treated with the compositions of Examples 1 and 2 had a sound sleep effect, a feeling of lethargy, and an improvement in fatigue compared to the tea drinking group of Comparative Examples 1 to 3.
이상과 같은 결과를 통해 본 발명의 차 조성물이 스트레스 완화 효능이 매우 우수함을 알 수 있으며, 이러한 기능을 통해 수험생, 직장인, 갱년기 중장년층의 스트레스 완화용 건강기능성 음료로서 이용 가능함을 확인할 수 있다. Through the above results, it can be seen that the tea composition of the present invention has a very excellent stress relieving effect, and through this function, it can be confirmed that it can be used as a health functional beverage for stress relieving for students, office workers, and menopausal middle-aged people.
Claims (4)
상기 차 조성물에 길초근, 달맞이꽃 종자, 감국, 감초, 홉, 레몬밤 및 라벤더가 첨가되는 것을 특징으로 하는 스트레스 개선용 건강기능성 차 조성물.According to claim 1,
A health functional tea composition for improving stress, characterized in that gilchogeun, evening primrose seeds, gamguk, licorice, hops, lemon balm and lavender are added to the tea composition.
상기 차 조성물은 건조된 각 원료 시료를 세절하여 준비한 후, 세절된 각 원료 시료를 물에 불린 후 160~170℃에서 8~12분 동안 가열하여 덖음하고, 30℃ 이하로 식히는 과정을 3~4회 반복하되, 반복할 때마다 덖음 온도를 8~10℃씩 낮추어 덖음하여 제조하는 것을 특징으로 하는 스트레스 개선용 건강기능성 차 조성물. According to claim 1 or 2,
The tea composition is prepared by cutting each dried raw material sample, soaking each raw material sample in water, heating at 160 to 170 ° C for 8 to 12 minutes, and cooling to 30 ° C or less. 3 to 4 A health functional tea composition for improving stress, characterized in that it is prepared by repeating the roasting process by lowering the roasting temperature by 8 to 10 ° C each time.
상기 차 조성물은 각 원료 시료에 물, C1~C4 알코올 또는 이들의 혼합용액을 사용하여 추출하여 제조하는 것을 특징으로 하는 스트레스 개선용 건강기능성 차 조성물. According to claim 1 or 2,
The tea composition is a health functional tea composition for improving stress, characterized in that prepared by extracting each raw material sample with water, C1-C4 alcohol, or a mixture thereof.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210058584A KR20220151393A (en) | 2021-05-06 | 2021-05-06 | Health functional tea composition for stress relief containing ginseng |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210058584A KR20220151393A (en) | 2021-05-06 | 2021-05-06 | Health functional tea composition for stress relief containing ginseng |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220151393A true KR20220151393A (en) | 2022-11-15 |
Family
ID=84042106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210058584A KR20220151393A (en) | 2021-05-06 | 2021-05-06 | Health functional tea composition for stress relief containing ginseng |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20220151393A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100483328B1 (en) | 2002-12-03 | 2005-04-14 | 키토일오삼(주) | Composition for Promotion of Fatigue Recovery And Process for Preparation Thereof, Medicine of Fatigue Recovery Using The Same |
| KR101346884B1 (en) | 2011-10-17 | 2014-01-06 | (주)풀무원홀딩스 | Composition for preventing and improving inflammatory bowel diseases and anti-fatigue comprising extract of maca as an active ingredient |
| KR101513240B1 (en) | 2013-06-17 | 2015-04-21 | 구미경 | A composition comprising extracts of herbal mixture for fatigue recovery as in gradient compounds |
| KR20160122110A (en) | 2015-01-21 | 2016-10-21 | 주식회사 엘지생활건강 | A composition for reinforcing immune function and anti-fatigue comprising fermented placenta and its use |
| KR101735151B1 (en) | 2010-07-27 | 2017-05-24 | 상하이 이노베티브 리서치 센터 오브 트레디셔날 차이니스 메디슨 | Anti-fatigue composition, formulation and use thereof |
| KR101804613B1 (en) | 2014-06-05 | 2017-12-04 | 재단법인 제주테크노파크 | Anti-stress Composition |
| KR101947786B1 (en) | 2017-10-16 | 2019-02-13 | 강수용 | Food Composition for Stress Relaxation, Fatigue Recovery or Athletic Performance Enhancement Comprising Extract of herb |
-
2021
- 2021-05-06 KR KR1020210058584A patent/KR20220151393A/en active IP Right Grant
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100483328B1 (en) | 2002-12-03 | 2005-04-14 | 키토일오삼(주) | Composition for Promotion of Fatigue Recovery And Process for Preparation Thereof, Medicine of Fatigue Recovery Using The Same |
| KR101735151B1 (en) | 2010-07-27 | 2017-05-24 | 상하이 이노베티브 리서치 센터 오브 트레디셔날 차이니스 메디슨 | Anti-fatigue composition, formulation and use thereof |
| KR101346884B1 (en) | 2011-10-17 | 2014-01-06 | (주)풀무원홀딩스 | Composition for preventing and improving inflammatory bowel diseases and anti-fatigue comprising extract of maca as an active ingredient |
| KR101513240B1 (en) | 2013-06-17 | 2015-04-21 | 구미경 | A composition comprising extracts of herbal mixture for fatigue recovery as in gradient compounds |
| KR101804613B1 (en) | 2014-06-05 | 2017-12-04 | 재단법인 제주테크노파크 | Anti-stress Composition |
| KR20160122110A (en) | 2015-01-21 | 2016-10-21 | 주식회사 엘지생활건강 | A composition for reinforcing immune function and anti-fatigue comprising fermented placenta and its use |
| KR101947786B1 (en) | 2017-10-16 | 2019-02-13 | 강수용 | Food Composition for Stress Relaxation, Fatigue Recovery or Athletic Performance Enhancement Comprising Extract of herb |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101144920B1 (en) | An Extract with Red Ginseng and Herbs | |
| KR101988959B1 (en) | Stress relieving or anti-fatigue composition containing enzymatic treatment white grub | |
| JP6404339B2 (en) | Composition having function of alleviating premenstrual syndrome and menstrual pain | |
| US20140072664A1 (en) | Daphne genkwa extracts, and pharmaceutical composition containing fractions of the extracts or compounds separated from the extracts as active ingredients for preventing or treating atopic dermatitis | |
| CN104336230A (en) | Mulberry leaf sweet tea and preparation method thereof | |
| CN108783155A (en) | A kind of sealwort, mulberry leaf, radix polygonati officinalis compatibility beverage and preparation method thereof | |
| EP1488797B1 (en) | Oral preprations having itching-relieving or antipruritic activity | |
| CN105722520A (en) | Sugar cane derived extracts and methods of treatment | |
| CN107865100A (en) | A kind of ginseng ginger juice health-care milk beverage and preparation method thereof | |
| KR102483300B1 (en) | Composition for improving muscle atrophy comprising ginsenoside Rf, ginsenoside composition comprising gincenoside Rf, or mixture thereof as an effective component | |
| US20180296615A1 (en) | Pharmaceutical composition or functional health food for preventing and treating metabolic diseases, containing water extract of pleurotus eryngii var. ferulae (pf.) as active ingredient | |
| CN114796295A (en) | Composition, food composition and pharmaceutical composition for promoting muscle differentiation and preventing muscle damage comprising ginseng extract | |
| CN111592959A (en) | Tonic three-penis wine and extraction method thereof | |
| CN101416722B (en) | Green bamboo health-care beverage and preparation method thereof | |
| TWI627962B (en) | Composition for improving blood glucose metabolism | |
| CN103920140B (en) | A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation | |
| KR20220151393A (en) | Health functional tea composition for stress relief containing ginseng | |
| CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
| KR101154031B1 (en) | Composition for Antifati gue containin g herbal mixture extract as in gredient compounds | |
| KR101089314B1 (en) | Composition containing euphobiasteroid for prevention, treatment or improvement of obesity | |
| CN110876418A (en) | Sterilizing and inflammation diminishing chocolate bean and preparation method thereof | |
| KR100533505B1 (en) | Health supplement food containing saponin derivatives isolated from ginseng radix for preventing and treating allergy-mediated disease | |
| CN104887759A (en) | Ginseng powder wine and preparation method thereof | |
| CN110801469A (en) | Functional food for regulating blood sugar and preparation method thereof | |
| CN103519308B (en) | Multifunctional traditional Chinese medicine functional drink and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right |